Answers are grounded in this paper and cite their sources.
Viral suppression has transformed HIV care, but it does not necessarily restore biological risk to that of people without HIV. In treated people with HIV, residual cardiometabolic, hepatic, vascular, and aging-related morbidity may reflect interactions between lasting effects of earlier HIV-related injury and ongoing biological stimulation during suppressive ART, including residual viral expression, gut barrier dysfunction, and microbial translocation. We propose the HIV immunometabolic legacy as an integrative framework linking these overlapping temporal dimensions to persistent immune activation, immunometabolic and mitochondrial alterations, epigenetic remodeling, and long-term tissue vulnerability. This Review examines the biological basis of this legacy and its clinical expression through adipose tissue dysfunction, metabolic dysfunction-associated steatotic liver disease, endothelial dysfunction, and subclinical vascular disease. We also discuss how early ART, statins, GLP-1 receptor agonists, lifestyle interventions, biomarkers, and imaging could support prevention, risk stratification, and future trials in long-term HIV care.
No takes yet. Share an insight, caveat, or question.
Pallotti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: